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Altered coagulation predisposing to thrombosis has been suggested to play an important role in ischemic stroke, 
although the extent of this association, of which coagulation 
factors are the most important mediators, and whether associa-
tion differs by ischemic stroke subtype, is unknown. One way 
to study thrombosis in the context of stroke is to consider com-
monalities in the underlying genetic liability to coagulation and 
ischemic stroke. Twin and family-based studies have demon-
strated substantial genetic contribution to plasma concentrations 
of hemostatic proteins in the general population1 and thrombosis 
Background and Purpose—Abnormal coagulation has been implicated in the pathogenesis of ischemic stroke, but how this 
association is mediated and whether it differs between ischemic stroke subtypes is unknown. We determined the shared 
genetic risk between 14 coagulation factors and ischemic stroke and its subtypes.
Methods—Using genome-wide association study results for 14 coagulation factors from the population-based TwinsUK 
sample (N≈2000 for each factor), meta-analysis results from the METASTROKE consortium ischemic stroke genome-
wide association study (12 389 cases, 62 004 controls), and genotype data for 9520 individuals from the WTCCC2 
ischemic stroke study (3548 cases, 5972 controls—the largest METASTROKE subsample), we explored shared genetic 
risk for coagulation and stroke. We performed three analyses: (1) a test for excess concordance (or discordance) in single 
nucleotide polymorphism effect direction across coagulation and stroke, (2) an estimation of the joint effect of multiple 
coagulation-associated single nucleotide polymorphisms in stroke, and (3) an evaluation of common genetic risk between 
coagulation and stroke.
Results—One coagulation factor, factor XIII subunit B (FXIIIB), showed consistent effects in the concordance analysis, the 
estimation of polygenic risk, and the validation with genotype data, with associations specific to the cardioembolic stroke 
subtype. Effect directions for FXIIIB-associated single nucleotide polymorphisms were significantly discordant with 
cardioembolic disease (smallest P=5.7×10−04); the joint effect of FXIIIB-associated single nucleotide polymorphisms was 
significantly predictive of ischemic stroke (smallest P=1.8×10−04) and the cardioembolic subtype (smallest P=1.7×10−04). 
We found substantial negative genetic covariation between FXIIIB and ischemic stroke (rG=−0.71, P=0.01) and the 
cardioembolic subtype (rG=−0.80, P=0.03).
Conclusions—Genetic markers associated with low FXIIIB levels increase risk of ischemic stroke cardioembolic 
subtype.   (Stroke. 2015;46:2069-2074. DOI: 10.1161/STROKEAHA.115.009387.)
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risk in the general population.2 Similarly, twin and family-based 
epidemiological studies, as well as more recent estimates of her-
itability from genome-wide association study (GWAS) arrays, 
suggest a substantial heritability for ischemic stroke.3–5
In a previous GWAS, we found that common genetic vari-
ants in the ABO gene were associated with ischemic stroke 
subtypes large-vessel disease (LVD) and cardioembolic (CE) 
stroke, but not with small-vessel disease (SVD).6 However, 
even though the GWAS approach surveys the entire genome 
for genetic associations, it typically queries one single nucleo-
tide polymorphism (SNP) at a time for association with the 
disease or trait of interest. Evidence from GWASs suggests 
that common complex traits, such as coagulation and ischemic 
stroke, are polygenic, influenced by many SNPs each contrib-
uting a relatively small effect. Recently developed approaches 
test a polygenic model of common genetic liability by con-
sidering aggregate SNP effects.7,8 We used GWAS results for 
multiple different coagulation factors and hypothesized that 
by aggregating the evidence for association in each coagula-
tion factor, we would be able to identify those coagulation 
factors that increase stroke risk and determine whether these 
differentially associate with stroke subtype.
Methods
Cohorts Studied
TwinsUK
The UK Adult Twin Registry (TwinsUK, http://www.twinsuk.
ac.uk9,10) was the sampling frame for a European Union–funded mul-
ticentre study that aimed to identify common genetic risk for blood 
coagulation and ischemic stroke (EuroCLOT, http://cordis.europa.
eu/result/rcn/52015_en.html6). Coagulation and fibrinolytic factors 
were selected on the basis of evidence for association with risk for 
atherothrombotic disorders, in a previous study estimating heritability 
of hemostatic factors.1 These hemostatic proteins are components of 
the coagulation pathway that is part of the defense mechanism against 
severe blood loss.11 The plasma protein assay protocols for the co-
agulation factors are described in detail elsewhere.1,6 Genotyping was 
performed in 3 batches on the Illumina Human Hap300 and Human 
Hap610-Quad arrays. Full details of genotyping and quality control 
are described elsewhere.6 The sample sizes for the 14 coagulation fac-
tors for which GWAS results were available are shown in Table. We 
used the coagulation GWAS results as a discovery sample.
METASTROKE
METASTROKE is a 15-cohort meta-analysis of ischemic stroke 
GWASs.12 The GWASs included ischemic stroke patients of European 
ancestry (Europe, North America, and Australia) with ancestry-
matched controls. Eleven studies used case–control methodology and 
were cross-sectional; the remaining 4 were prospective, population-
based cohorts. Full details of the populations and analysis are de-
scribed elsewhere.12 We used METASTROKE meta-analysis results 
as the target sample.
WTCCC2
The Wellcome Trust Case Control Consortium 2 (WTCCC2) ischemic 
stroke sample—the largest METASTROKE subsample—included a 
German (1174 cases and 797 controls) and a UK sample (2374 cases 
and 5175 controls).13 After combining the UK and German samples, 
we removed 16 population outliers. We used the WTCCC2 stroke 
sample genotypes as our validation sample.
In all METASTROKE studies, including the WTCCC2 subsam-
ple, stroke was defined as a typical clinical syndrome with radiological 
confirmation. Stroke subtyping was performed with the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) classification system.14 
Brain imaging with computed tomography or magnetic resonance im-
aging was undertaken for >95% of cases in all the METASTROKE 
cohorts (sample sizes are included in Table).
Study Design
SNP Selection
We used a thinned set of coagulation-associated risk SNPs for both 
the concordance and polygenic risk analyses because SNP correla-
tion because of linkage disequilibrium may inflate test statistics from 
polygenic approaches.
ClumpingFrom the TwinsUK SNPs imputed to HapMap2, 
we first selected only SNPs common to both genotyping plat-
forms used. For all SNPs with a minor allele frequency ≥0.05, we 
then used the clumping routine implemented in PLINK,15 which 
selects SNPs based on association P value and linkage disequi-
librium, using standard parameter values (linkage disequilibrium 
threshold of r2 ≤0.25 in the HapMap CEU reference panel16; 
distance window of 300 kb). Clumping resulted in a subset of 
≈70 000 near-independent SNPs for each coagulation factor. 
The ratio of estimated number of independent SNPs to observed 
(clumped) SNPs, the so-called effective ratio,17 was ≈0.93.
Inclusion ThresholdsWe repeated each coagulation factor-
stroke subtype analysis at multiple SNP-association P value 
inclusion thresholds. We ranked the clumped SNPs by their 
Table.  Study Sample Sizes
Phenotype N
TwinsUK (genotype, phenotype, and GWAS results data)
  Factor VII antigen, IU/mL 1374
  Factor VIIC percent, % 1787
  Factor VIII antigen, IU/mL 2504
  Factor X antigen, U/mL 2600
  Factor XII antigen, IU/mL 2595
  Factor XIII activity, % 2598
  Factor XIII subunit A antigen, IU/mL 2599
  Factor XIII subunit B antigen, IU/mL 2601
  Von Willebrand factor antigen, IU/mL 2584
  Prothrombin antigen, IU/mL 2596
  D-dimer, ng/mL 2762
  Plasminogen activator inhibitor antigen, ng/mL 2590
  Tissue-type plasminogen activator antigen, ng/mL 2564
  Fibrinogen, g/L 2607
METASTROKE (GWAS meta-analysis results data)
  Cardioembolic subtype 2365 cases
  Large vessel disease 2167 cases
  Small vessel disease 1894 cases
  All ischemic stroke 12 389 cases; 62 004 
controls
WTCCC2 (genotype and phenotype data)
  Cardioembolic subtype 790 cases
  Large vessel disease 844 cases
  Small vessel disease 580 cases
  All ischemic stroke 3548 cases; 5972 
controls
GWAS indicates genome-wide association study.
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evidence for association in the TwinsUK discovery GWASs 
and created 7 overlapping SNP subsets for all SNPs signifi-
cant at P ≤{0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5}, for each factor. 
These P values define increasingly liberal inclusion thresh-
olds. Polygenic approaches show that more liberal inclusion 
thresholds benefit from true associations that exist all the way 
down a P value ranked list of genetic markers, far below the 
level usually considered as genome-wide significant.7
Multiple Testing
We estimated the number of independent coagulation variables using 
a Nyholt correction18 of the coagulation factor polygenic risk scores 
(PRSs). The number of independent tests from the 14 coagulation 
PRSs was estimated at 13.4, which highlights the low level of poly-
genic correlation among the coagulation factors themselves. We used 
a conservative Bonferroni-corrected probability value of P≤0.05/
(13.4×4), where 4 is the number of stroke subtypes, to control for 
multiple testing in the discovery and target samples using GWAS 
summary statistics; we used P≤0.05 for focused follow-up on geno-
type data in the validation subsample.
Statistical Analysis
We used 3 approaches to test for shared genetic influence on coagula-
tion traits and ischemic stroke and its subtypes, as follows:
Concordance of Genetic Effects
We first tested for greater than expected concordance (or discordance) 
in direction of effects (β-estimate, odds ratio) between each coagulation 
factor–stroke subtype pair. At each P value inclusion threshold, we used 
an Exact Binomial Test to assess whether there was a greater than chance 
agreement in effect direction. This approach simply counts the number 
of SNPs acting in the same direction, regardless of magnitude of effect 
and tests the expectation under the null hypothesis of 50% agreement.
Polygenic Risk Scores
Next we assessed shared genetic risk (pleiotropy) between each co-
agulation factor and each stroke subtype by summing over all SNP 
effects in the target sample and weighting by evidence for association 
in the coagulation discovery sample. For a given set of SNPs, an in-
dividual’s PRS is the sum of risk alleles they have weighted by allele 
effect size in the discovery trait. It represents their genetic risk for 
the discovery trait. The method described below does not explicitly 
calculate the coagulation PRS for each individual but rather estimates 
the association between such a score and the target trait.
Summary Statistics
With summary data, the joint effect of the SNPs in each subset was 
estimated by a weighted mean of individual SNP effects, that is, sum-
ming the SNP effects in the stroke target sample weighted by their 
effects in the coagulation discovery sample. In a regression model 
predicting the target sample outcome, y c a e= + +PRS , the PRS 
 coefficient can be estimated by 
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where β˘
i
 are the discovery sample SNP effects, ωi  are the target sample 
SNP effects, and si  are the target sample standard errors for the ith SNP. 
Without individual-level genotype data, this method does not explicitly 
estimate a PRS—only its effect. The joint SNP effect estimate inherits co-
variate adjustment from covariates included in the contributing GWASs, 
for example, population structure axes.19 The approach (described in 
detail elsewhere20) is implemented in the package gtx (gtx: Genetics 
ToolboX, http://cran.r-project.org/web/packages/gtx)21 in the language 
and statistical computing environment R (http://www.R-project.org/).22
Genetic Covariance
Finally, using genotype-level data for the TwinsUK sample and the 
UK and German subsamples of the WTCCC2, we validated findings 
from the concordance and polygenic risk analyses by estimating the 
phenotypic covariation between the 2 traits (ie, pleiotropy—rGSNP), 
as well as genetic contribution to phenotypic variance within trait (ie, 
univariate SNP heritability—h2SNP). These estimates are based on dis-
tant relatedness calculated from common SNPs. Estimation of SNP 
heritability and pleiotropy between complex traits using SNP-derived 
genomic relationships and restricted maximum likelihood is imple-
mented in the program Genome-wide Complex Trait Analysis.8,23 
Specifically, we used the genetic covariance estimation with geno-
type data to validate findings from the concordance and polygenic 
risk analyses with GWAS summary results.
Results
Concordance of Genetic Effects
Three coagulation factors showed excess concordance (or dis-
cordance) of effect direction with stroke: SNPs significant at 
P≤0.3 in factor XIII subunit B (FXIIIB) were significantly dis-
cordant with the CE subtype (most significant P=5.7×10−04); 
SNPs significant at P≤0.05 through P≤0.2 in factor VIII 
(FVIII) were significantly concordant with the SVD subtype 
(most significant binomial P=6.5×10−04), but not at more lib-
eral inclusion thresholds; SNPs significant at P≤0.3 only in 
Von Willebrand factor were significantly concordant with the 
SVD subtype. Figure 1 summarizes the evidence for excess 
concordance (or discordance) of effect between the 14 coagu-
lation factors and ischemic stroke and its 3 subtypes.
Polygenic Risk Scores
All ischemic stroke and the CE subtype, but not the LVD or 
SVD subtypes, were significantly associated with coagulation 
polygenic risk. For all ischemic stroke, PRSs from 3 coagula-
tion factors were significant: FVIIC% at inclusion thresholds 
P≤0.2 and 0.4 (most significant P=4.9×10−04); FX at inclusion 
threshold greater than P≤0.4 (most significant P=1.5×10−04); 
and FXIIIB for inclusion thresholds greater than P≤0.01 
(most significant P=1.8×10−04). For the CE subtype, FXIIIB 
was significantly predictive at all inclusion thresholds greater 
than P≤0.2 (most significant P=1.7×10−04), although the pro-
portion of variance explained (R2) was modest (<1%) at all 
inclusion thresholds. FXIIIB was the one coagulation fac-
tor that showed consistent effects in both the concordance 
analyses and the PRS analyses. Figure 2 shows the increasing 
explanatory power of FXIIIB for all ischemic stroke and CE, 
as we increased the number of FXIIIB-associated risk variants 
included in the stroke prediction model.
In the target sample analyses, we found that genetic varia-
tion associated with lower FXIIIB levels was consistently 
predictive of higher stroke risk: genetic risk was significantly 
discordant for FXIIIB and stroke, and a negative association 
between polygenic risk based on FXIIIB indicates that con-
trols had more FXIIIB-associated SNPs than stroke cases.
Genetic Covariation
Finally, to validate the association with FXIIIB using an alter-
native approach, we directly estimated from genotype data 
the genetic covariation between stroke and FXIIIB. We found 
evidence of a significantly high level of shared genetic risk for 
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FXIIIB–all ischemic stroke (rGSNP=−0.71, SE=0.81, P=0.01, 
N=10,668; h2SNP FXIIIB =0.13, SE=0.28; h2SNP ischemic 
stroke =0.45, SE=0.04). Similarly, bivariate GREML analysis 
for FXIIIB–CE suggested a significantly high degree of com-
mon genetic risk (rGSNP=−0.80, SE=0.90, P=0.03, N=7917; 
h2SNP FXIIIB =0.13, SE=0.28; h2SNP CE =0.34, SE=0.05). 
Figure 2. Common polygenic risk for factor XIII subunit B (FXIIIB) and stroke. The figure shows the polygenic risk prediction of FXIIIB-
associated risk for all ischemic stroke and the ischemic stroke subtypes. ALL indicates all ischemic stroke; CE, cardioembolic subtype; 
GWAS, genome-wide association studies; PDISCOVERY, P value inclusion threshold defining SNP subsets from coagulation factor GWASs; 
R2, variance explained by the polygenic risk score (PRS; pseudo R2 from a logistic regression); and SNP, single nucleotide polymorphism. 
*Inclusion thresholds that significantly predict stroke status (bold asterisk shows most significant threshold).
Figure 1. Common direction of effects in coagulation and stroke. P value inclusion thresholds define SNP subsets based on significance 
in the coagulation factor genome-wide association studies (GWASs). For example, at P≤0.5 (the most liberal inclusion threshold), half the 
SNPs from each GWAS discovery study were used to test for concordance of effect between the coagulation discovery samples and the 
stroke target samples. The y-axes show evidence of excess similarity (or dissimilarity) in direction of effect (negative log10 P values from an 
Exact Binomial Test). Each line in a plot represents strength of evidence that a particular coagulation factor’s genetic risk in aggregate acts 
in the same (or opposite) direction to the genetic risk for stroke. Factors with significant similarity (or dissimilarity) of effect are highlighted—
these traits survive multiple test correction (P≤0.5/(13.4×4)) and lie outside the grey-shaded area. ALL indicates all ischemic stroke; CE, 
cardioembolic subtype; FVIII, factor VIII; LVD, large-vessel disease subtype; –log10P value, P value from the binomial test for concordance; 
PDISCOVERY, P value inclusion threshold defining SNP subsets; SVD, small-vessel disease subtype; and VWF, Von Willebrand factor.
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The negative genetic covariance between FXIIIB and both 
all ischemic stroke and the CE subtype indicates that genetic 
variation predisposing to low levels of FXIIIB is associated 
with increased risk for stroke. A negative genetic correlation 
is consistent with our results above: FXIIIB had discordant 
SNP effects with CE stroke and the FXIIIB-associated PRS 
for stroke was lower in cases.
The large standard errors associated with these estimates 
are typical for small sample sizes in bivariate GREML analy-
ses. From the combined TwinsUK-WTCCC2 sample, we 
excluded one individual from each pair with an estimated 
relatedness above 10%. We chose this cut-off (which removes 
up to first cousin relationships) because of the coagulation 
sample size: for example, of the 10 668 individuals in the 
FXIIIB-ischemic stroke analysis, 1940 were TwinsUK sam-
ples. Using the default Genome-wide Complex Trait Analysis 
relatedness cut-off of 2.5%, we found similarly high point 
estimates with much larger standard errors (FXIIIB-ischemic 
stroke: rGSNP=−0.85, SE=2.69, P=0.06), suggesting that a 
larger sample would yield similar pleiotropy estimates with 
narrower confidence intervals.
Discussion
Here, we used statistical genetic approaches to evaluate the 
genetic influence of coagulation traits on ischemic stroke and 
its subtypes. Our results indicate that the aggregate effect of 
risk SNPs for the plasma protein FXIIIB has a small, but sig-
nificant effect on risk for ischemic stroke, specifically for the 
CE subtype, but not LVD or SVD stroke. Genetic factors that 
increased levels of FXIIIB were associated with decreased 
ischemic stroke risk. This result was identified using 3, but 
related, statistical analysis approaches.
A common genetic contribution to higher levels of FXIIIB 
and lower risk of ischemic stroke might seem counterintuitive. 
Two A subunits (FXIIIA) and 2 B subunits (FXIIIB) make up 
the FXIII tetramer whose main function is to strengthen and 
protect the fibrin clot against degradation during clot forma-
tion. Individuals with FXIII deficiency manifest a severe sus-
ceptibility to hemorrhage (or bleeding diathesis).24 However, 
as well as its clot stabilizing or prothrombotic effects, FXIII 
also has an antithrombotic effect by inhibiting platelet aggre-
gation.25 That said, it is not clear what effect high plasma 
levels of free-floating FXIIIB (measured by the assay) would 
have on levels of the FXIII tetramer and how a change in lev-
els of FXIII would affect the balance of its pro- and antithrom-
botic effects. At a 2.8-year poststroke follow up for mortality, 
FXIIIB and FXIIIA have been found to be present at signifi-
cantly higher levels in survivors compared with those that had 
died.26 One particular polymorphism, FXIIIVal34Leu, has 
been reported to provide a protective effect against venous 
thromboembolism and myocardial infarction in Caucasians (in 
the absence of insulin resistance).27,28 The same polymorphism 
conveys no protective effect in South Asians, known to have 
higher levels of insulin resistance. FXIIIB was in fact found to 
be higher among South Asian ischemic stroke cases even after 
accounting for insulin resistance.29 However, as polygenic risk 
scoring approaches by design capture net genetic effects, the 
risk score based on FXIIIB-associated SNPs is the sum of 
many SNPs (of which the base change at the FXIIIVal34Leu 
polymorphism is just one), potentially acting both to increase 
and decrease levels of FXIIIB. The biological role of FXIIIB 
is complex, and further research is required to understand the 
specific mechanism underlying the observed protective effect.
In contrast, we found no association with LVD. 
Thromboembolism is believed to be the primary pathophysi-
ological mechanism in LVD as in CE, but the underlying 
thrombotic mechanisms may differ in LVD. This is supported 
by clinical trial data, suggesting antiplatelet agents seem to be 
the most effective secondary prevention approach in LVD,30 
although it is worth noting that the superiority of antiplate-
lets over anticoagulants for ischemic stroke of non-CE origin 
is not unequivocal.31 In contrast, anticoagulants have consis-
tently been shown to be more effective than antiplatelets in 
CE stroke. There was also no association with SVD, and this 
would be consistent with a lack of pathophysiological evi-
dence linking thrombosis with this stroke subtype.32
This study does have limitations. First, although our 
stroke sample was relatively large, numbers of cases in the 
subtype analyses were necessarily smaller. Similarly, sample 
sizes for the coagulation factor GWASs were modest. Second, 
we benefitted from aggregating evidence across many SNPs, 
including those that did not achieve genome-wide signifi-
cance in earlier genetic studies of coagulation and stroke, but 
this provides no resolution at individual SNPs, and we were 
consequently unable to comment on specific FXIIIB poly-
morphisms previously reported to be associated with throm-
botic disease (stroke). Third, our final technique that tested 
genetic covariation used a subset of the METASTROKE 
sample and so was not a true replication in an independent 
data set. However, because the genetic covariation technique 
used SNP-level information for each individual in both the 
coagulation and stroke studies (as opposed to summary statis-
tics from the overall GWASs), we included it as a validation 
of polygenic risk estimation using only GWAS meta-analysis 
results from the stroke studies.
A recent review of the role of FXIII in the risk for throm-
botic diseases found only 4 studies that investigated FXIII 
levels and ischemic stroke.25 It concluded that no clear pic-
ture emerged and called for well-designed studies with clear 
differentiation of stroke subtype to clarify the problem. By 
aggregating evidence across the entire genome, our study 
found a link between the genetic influence on FXIIIB levels 
and the CE subtype, narrowing the focus to a specific subtype 
and highlighting a direction for further investigation into the 
mechanism behind the role of FXIIIB in aberrant coagulation 
and the pathogenesis of ischemic stroke.
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